Compile Data Set for Download or QSAR
Report error Found 104 Enz. Inhib. hit(s) with all data for entry = 9984
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433368(US10562850, Compound 61b | US11066360, Compound 61...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433370(US10562850, Compound 18b | US11066360, Compound 18...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433373(US10562850, Compound 18a | US11066360, Compound 18...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433374(US10562850, Compound 62c | US11066360, Compound 62...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433382(US10562850, Compound 64g | US11066360, Compound 64...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433385(US10562850, Compound 65b | US11066360, Compound 65...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433388(US10562850, Compound 36d | US10562850, Compound 37...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433394(US10562850, Compound 31i | US11066360, Compound 31...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433397(US10562850, Compound 32a | US11066360, Compound 32...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433403(US10562850, Compound 34d | US11066360, Compound 34...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433407(US10562850, Compound 14h | US11066360, Compound 14...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433412(US10562850, Compound 29e | US11066360, Compound 29...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433413(US10562850, Compound 68a | US11066360, Compound 68...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433415(US10562850, Compound 30a | US11066360, Compound 30...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433416(US10562850, Compound 69a | US11066360, Compound 69...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433418(US10562850, Compound 72c | US11066360, Compound 72...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433419(US10562850, Compound 70c | US11066360, Compound 70...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433422(US10562850, Compound 71a | US11066360, Compound 71...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433423(US10562850, Compound 55a | US11066360, Compound 55...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433426(US10562850, Compound 56a | US11066360, Compound 56...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433428(US10562850, Compound 38d | US11066360, Compound 38...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433429(US10562850, Compound 77a | US11066360, Compound 77...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433431(US10562850, Compound 39h | US11066360, Compound 39...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433432(US10562850, Compound 57d | US11066360, Compound 57...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433434(US10562850, Compound 40a | US11066360, Compound 40...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433435(US10562850, Compound 41a | US11066360, Compound 41...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433439(US10562850, Compound 58j | US11066360, Compound 58...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433441(US10562850, Compound 48d | US11066360, Compound 48...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433443(US10562850, Compound 59d | US11066360, Compound 59...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433448(US10562850, Compound 52d | US11066360, Compound 52...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433450(US10562850, Compound 81h | US11066360, Compound 81...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433451(US10562850, Compound 53d | US11066360, Compound 53...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433453(US10562850, Compound 79a | US11066360, Compound 79...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433454(US10562850, Compound 51b | US11066360, Compound 51...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433455(US10562850, Compound 46k | US11066360, Compound 46...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433456(US10562850, Compound 78a | US11066360, Compound 78...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433457(US10562850, Compound 73a | US11066360, Compound 73...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433460(US10562850, Compound 74a | US11066360, Compound 74...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433463(US10562850, Compound 54g | US11066360, Compound 54...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433449(US10562850, Compound 42l | US10562850, Compound 43...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433469(US10562850, Compound 75e | US11066360, Compound 75...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433367(US10562850, Compound 17b | US11066360, Compound 17...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433371(US10562850, Compound 30b | US11066360, Compound 30...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433366(US10562850, Compound 3a | US10562850, Compound 1p ...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433375(US10562850, Compound 4g | US11066360, Compound 4g)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433377(US10562850, Compound 63g | US11066360, Compound 63...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433393(US10562850, Compound 23b | US11066360, Compound 23...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433406(US10562850, Compound 35a | US11066360, Compound 35...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433424(US10562850, Compound 4f | US11066360, Compound 4f)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433438(US10562850, Compound 47d | US11066360, Compound 47...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 104 total ) | Next | Last >>
Jump to: